Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor

(2018) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease

(2017) Abhijeet Yadav et al.   INFLAMMATORY BOWEL DISEASES

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

(2017) Carl Eriksson et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study

(2016) A. Stallmach et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

(2016) Parambir S Dulai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation

(2016) Carlos Taxonera et al.   DIGESTIVE DISEASES AND SCIENCES

The safety of vedolizumab for ulcerative colitis and Crohn's disease

(2016) Jean-Frédéric Colombel et al.   GUT

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease

(2016) Uri Kopylov et al.   Therapeutic Advances in Gastroenterology

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD

(2014) Parambir S Dulai et al.   GUT

An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis

(2014) Claire Manginot et al.   GUT

Targeting TNF-α for the treatment of inflammatory bowel disease

(2013) Thomas Billiet et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Towards personalized care in IBD

(2013) Mark E. Gerich et al.   Nature Reviews Gastroenterology & Hepatology

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

(2012) Christina Ha et al.   Clinical Gastroenterology and Hepatology

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

How Rapidly Should Remission Be Achieved?

(2010) Kim L. Isaacs   DIGESTIVE DISEASES